The U.S. Just Authorized Nvidia Chip Sales to China. Here's What Investors Need to Know.

Nvidia, which lost access to China this year — a market that made up about 13% of fiscal sales and forced a roughly $1 billion inventory charge and removal of China from guidance — may be allowed back after the U.S. signaled it will permit export of existing H200 GPUs to approved Chinese customers in return for a reported 25% revenue-sharing arrangement, according to President Trump; Nvidia has signaled support and the H200 is immediately deployable (the newer Blackwell architecture remains restricted). Given Nvidia’s >70% gross margins and management estimates that China could represent tens of billions in AI demand, restoration of sales would be a material growth catalyst, but the timeline, regulatory implementation, and China’s push for domestic chips (plus prior talks about a 15% revenue share) leave near-term upside and execution risk uncertain.

Analysis

President Trump announced via Truth Social that Nvidia may be permitted to export existing H200 GPUs to approved customers in China, with a reported requirement that Nvidia share 25% of revenue from those sales with the U.S.; Nvidia signaled support and the company previously lost access to China earlier this year after U.S. export controls, a market that represented about 13% of Nvidia's fiscal sales and contributed to a roughly $1 billion inventory charge and the removal of China from guidance. The H200 is an existing, more powerful product than the H20 that Nvidia had engineered to comply with prior controls, which implies faster potential rollout if licenses are granted; Nvidia cannot export its latest Blackwell architecture under current terms. China’s government has discouraged use of H20 and promoted domestic chips, and an August industry understanding had contemplated a 15% revenue share, so the newly reported 25% term and any licensing timelines are key variables. Nvidia has maintained gross margins above 70% recently and management has described China AI demand as potentially $50 billion this year and much larger by decade-end, so restoring access would be a material growth catalyst, but timing, regulatory implementation, revenue-sharing dilution and Chinese substitution policy create meaningful execution and near-term upside risk, keeping investor outcomes dependent on concrete license approvals and uptake metrics.

Key Decisions for Investors

• Monitor for formal U.S. Treasury/BIS license language and an official timeline before materially increasing exposure, as terms and approvals will determine economic benefit and compliance risk
• If official approvals and customer lists emerge, consider phased position increases to capture upside given H200’s immediate deployability, while accounting for the reported 25% revenue share that will compress net margins
• Maintain hedges or size positions conservatively until clear evidence of Chinese customer adoption appears (order flow, reseller activity, or updated guidance), because China’s push for domestic chips and policy shifts present substantive execution risk